NanOlogy

I believe that to solve the toughest challenges in oncology, we will need to establish a new community to foster innovation around intratumoral therapies and procedures. Between the incredible up-and-coming technologies, drugs and devices, coupled with strong expertise and talent across the field, together we can reach our goal of delivering the next evolution in the standard of care for cancer. In my latest LinkedIn article, I share some insights into the #IntratumoralTherapy space, how Interventional Oncology at Johnson & Johnson is committed to building this community, and where you can connect with us in the coming months. #MyCompany

An article published in Pancreatology by Somashekar Krishna, a key clinical investigator for our mucinous pancreatic cyst clinical trial, reports further insights from a follow-on expanded access protocol he led of intracystic LSAM-PTX in pts with nonoperable high-risk BD-IPMNs. https://lnkd.in/gQSjCs-E

The?Advanced Research Projects Agency for Health (ARPA-H) Customer Experience Hub gives a warm welcome to one of our newest Spoke members,?NanOlogy.?As a Spoke for the network,?NanOlogy?uses its unique capabilities to accelerate better health for all. In particular, NanOlogy is advancing intratumoral drug therapy. Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation. The NanOlogy commercial scale GMP production platform precipitates dissolved drug substances with sonication and compressed supercritical carbon dioxide to form stable large surface area microparticles (LSAMs) of pure drug containing no excipients or coating agents. LSAMs have a disproportionately large surface area to particle size ratio that enables retention of particles at the disease site and continuous local drug release over time with gradual systemic clearance at subtoxic levels. Initial investigational drugs are LSAM-PTX and LSAM-DTX, which have completed clinical trials in multiple solid tumors with excellent tolerability and promising signs of tumor response and immunomodulation. NanOlogy has established feasibility of forming LSAMs in multiple drug classes including taxanes, cisplatin, TKIs, and PARPIs. Therapeutic potential exists across the cancer disease spectrum with NanOlogy intratumoral investigational drugs. In local disease, the potential to delay or prevention of solid tumor progression as an alternative to organ removal or other invasive procedures as the only curative options. In metastatic disease, the potential for immunomodulation by sustained primary tumor cell death to boost the local and systemic response to immunoncology therapies without adding systemic toxicity. To become a Spoke alongside?NanOlogy?and our growing population of over 330 other members, complete the membership application available at?https://lnkd.in/gT4VY72J.?#ARPAH

Honored to co-author this just published research article in Oncology and Therapy. In all, we have more than 30 publications on clinical and preclinical research supporting our LSAM drug platform. https://lnkd.in/gNcEWaae